Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up – Still a Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $29.90, but opened at $32.25. Dianthus Therapeutics shares last traded at $30.56, with a volume of 27,707 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DNTH shares. Wedbush reduced their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Oppenheimer began coverage on shares of Dianthus Therapeutics in a research note on Thursday, October 3rd. They set an “outperform” rating and a $48.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Thursday, September 26th. Finally, Robert W. Baird initiated coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $45.14.

Dianthus Therapeutics Stock Down 2.8 %

The business’s 50 day simple moving average is $27.75 and its 200 day simple moving average is $26.45. The company has a market capitalization of $853.20 million, a PE ratio of -5.40 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently bought and sold shares of DNTH. Bain Capital Life Sciences Investors LLC purchased a new stake in shares of Dianthus Therapeutics in the first quarter worth approximately $89,761,000. RA Capital Management L.P. acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at $69,990,000. Vanguard Group Inc. grew its holdings in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Dianthus Therapeutics in the first quarter valued at about $11,251,000. Finally, Great Point Partners LLC increased its position in Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after purchasing an additional 132,929 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.